28 April 2021
Federal government signs contract for drug to treat COVID-19
On the advice of the Swiss National COVID-19 Task Force, the Federal Office of Public Health has signed a contract with Roche Pharma (Switzerland) Ltd to purchase a promising drug to treat coronavirus (SARS-CoV-2). It is a combination of monoclonal antibodies. The first deliveries are planned for mid-May. The contract value is confidential.
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Swissmedic: Haemovigilance Annual Report 2025
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
Swissmedic: Revision of the Guidance document Authorisation Biosimilar